Related Experiment Video
Updated: May 21, 2026
06:28
E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
IBS patients' willingness to take risks with medications
Brian E Lacy1, Kelly K Everhart, Kirsten T Weiser
1Division of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA. Brian.E.Lacy@Hitchcock.org
The American Journal of Gastroenterology
|June 6, 2012
Summary
Irritable bowel syndrome (IBS) patients with severe symptoms show greater willingness to accept medication risks for symptom relief. Understanding patient risk aversion is crucial for effective IBS treatment counseling.
Area of Science:
- Gastroenterology
- Behavioral Science
- Clinical Psychology
Background:
- Irritable bowel syndrome (IBS) significantly impacts quality of life.
- Patient decision-making regarding treatment, including medication risks, is complex.
- Understanding risk tolerance in IBS patients is essential for personalized care.
Purpose of the Study:
- To investigate impulsivity and risk-taking behaviors in IBS patients.
- To assess the willingness of IBS patients to accept medication risks.
- To explore factors influencing medication risk-taking in IBS.
Main Methods:
- Validated questionnaires were used to assess the illness experience of IBS patients.
- A standard gamble technique evaluated patient willingness to take medication risks.
- Data analysis correlated symptom severity, impulsivity, age, gender, and duration of illness with risk-taking behavior.
Main Results:
- Patients with severe IBS symptoms exhibited a higher willingness to accept significant medication risks.
- Impulsivity, age, gender, and symptom duration were not significantly associated with medication risk-taking.
- A hypothetical cure for IBS symptoms was associated with acceptance of a median 1% risk of sudden death.
Conclusions:
- IBS patients demonstrate a significant willingness to undertake substantial medication risks for symptom resolution.
- Physicians need to assess and comprehend individual IBS patient risk aversion for optimal counseling.
- Tailoring treatment discussions to patient risk tolerance can improve therapeutic outcomes.
Related Concept Videos
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:21Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...